Polyserositis as a Probable Early Manifestation of Systemic Lupus Erythematosus

José Guillermo Cabanillas López¹ and Juan De Dios Yépez Florian^1,

¹Internal Medicine Department, Alta Complejidad Virgen de la Puerta Hospital, Trujillo, 13013, Peru

Cite this paper:
José Guillermo Cabanillas López and Juan De Dios Yépez Florian. Polyserositis as a Probable Early Manifestation of Systemic Lupus Erythematosus. American Journal of Medical Case Reports. 2022; 10(7):173-177. doi: 10.12691/ajmcr-10-7-3

Abstract

The involvement of serosas is a pathological condition shared by various diseases among which is systemic lupus erythematosus as an example of immunological condition. Polyserositis involves damage to various organs, thus overshadowing the prognosis of patients. We present the report of a case of a 49-year-old female patient with pericardial and pleural effusion of approximately 5 months of evolution, accompanied by clinical situations that justified the presence of such serositis which distracted the diagnostic process of lupus, in addition to an inconsistent elevation of antinuclear antibodies that caused a delay in treatment supported by the current criteria for diagnosis of systemic lupus erythematosus, favoring the fatal outcome of the patient. We suggest that these new diagnostic criteria for systemic lupus erythematosus prioritize greater value for clinical manifestations, since initiating the diagnostic algorithm based on laboratory criteria can lead to significant delays in the therapeutic approach with disastrous results for patients suffering from this disease.

Keywords:
systemic lupus erythematosus pericardial effusion pleural effusion antinuclear antibodies

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., Jayne, D., Cervera, R., Costedoat-Chalumeau, N., Diamond, B., Gladman, D. D., Hahn, B., Hiepe, F., Jacobsen, S., Khanna, D., … Johnson, S. R. (2019). 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis & Rheumatology, 71(9), 1400-1412.
[2]	Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019 Jan; 96: 1-13.
[3]	Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med. 2019 Feb 8; 6(1): e000310.
[4]	González Jiménez, D., Mejía Bonilla, S., & Cruz Fallas, M. (2021). Lupus eritematoso sistémico: enfoque general de la enfermedad. Revista Medica Sinergia, 6(1), e630.
[5]	Bertsias, G., Fanouriakis, A., & Boumpas, D. T. (2017). Treatment of systemic lupus erythematosus. In G. S. Firestein, R. C. Budd, S. E. Gabriel, I. B. McInnes, & J. R. O’Dell (Eds.), Kelley and Firestein’s Textbook of Rheumatology (pp. 1368-1388.e5). Elsevier.
[6]	Systemic lupus erythematosus (SLE) clinical presentation. (2022, June 21). Medscape.com. https://emedicine.medscape.com/article/332244-clinical.
[7]	Ferretti, C., & La Cava, A. (2016). Overview of the pathogenesis of systemic lupus erythematosus. In G. C. Tsokos (Ed.), Systemic Lupus Erythematosus (pp. 55-62). Elsevier.
[8]	Rind, A., & Isenberg, D. A. (2022). Systemic Lupus Erythematosus. In T. Kenakin (Ed.), Comprehensive Pharmacology (pp. 447-460). Elsevier.
[9]	Losada I, González-Moreno J, Roda N, Ventayol L, Borjas Y, Domínguez FJ, Fernández-Baca V, García-Gasalla M, Payeras A. Polyserositis: a diagnostic challenge. Intern Med J. 2018 Aug; 48(8): 982-987.
[10]	Granja Romero, E., Trinidad Sanjosé, J. C., González Rivero, C., & Del Río Romero, D. (2010). Serositis pleuroperitoneal como manifestación de un lupus inducido por pirazolonas (metamizol). Reumatologia clinica, 6(2), 117-118.
[11]	Zampeli, E., Skopouli, F. N., & Moutsopoulos, H. M. (2018). Polyserositis in a patient with active systemic lupus erythematosus: A case of pseudo-pseudo Meigs syndrome. The Journal of Rheumatology, 45(6), 877-878.